Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
In the parlance of drug dispensing, “white bagging” is the term used when insurers require certain prescribed drugs to be dispensed from a specific specialty pharmacy and shipped directly to a practice, hospital, or clinic for patient administration. This is increasingly the case with infusion therapies for the treatment of cancer. Many providers are taking a stand against insurer mandates for …
Association of Community Cancer Centers Association of Community Cancer Centers Treasurer’s Report to the Board of Trustees Financial Reports for December 2023 Douglas B. Flora, MD, LSSBB Variance Report Membership Renewals: As of the end of December, 530 Cancer Program Members (or 84.4%) have renewed their membership and 114 Individual Members (or 51.8%) have renewed. The budget …
The ACCC Oncology Reimbursement Meetings (ORMs) help all members of the multidisciplinary cancer care team navigate the annual changes in oncology reimbursement and regulations— while improving their knowledge on effective strategies for success in an everchanging oncology landscape. In this episode, CANCER BUZZ speaks with Jordan Karwedsky, financial counselor, Green Bay Oncology, about her …
The leading education and advocacy organization for the cancer care community.
Clinical Investigation in a Managed Care Setting Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Clinical Investigation in a Managed Care Setting Cary A. Presant To cite this …
Radiation Therapy Reimbursement: A Comparison of Hospital versus Freestanding Radiation Therapy Site Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Radiation Therapy Reimbursement: A …
MJ10-Infusion-of-Evidence-Balancing-Patient-Desires-with-Environmental-Evidence
ACCC's Ninth Oncology Presidents' Retreat ACCC's Ninth Oncology Presidents' Retreat A New Administration and Continued Threats to Cancer Care Leaden from many of the nation's cancer patient advocacy organizations gathered for their own briefing about legislative and regulatory issues. L eaders from nationaloncology associations,state oncology societies,and cancer patient advoca-cy organizations …
Decatur Memorial Hospital Cancer Care Institute Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Decatur Memorial Hospital Cancer Care Institute Research in the “Pride of the Prairie” …
MA10-First-Person
MJ07-Tools
MJ02-Profile
OI | Vol. 36, No. 2, 2021 | accc-cancer.org 9 Approved Drugs • On Feb. 5, 2021, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s (bms.com) Breyanzi® (lisocabtagene maraleucel), a CD19- directed chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic …
MA03-Designing-an-Efficient-Cancer-Care-Environment
tools 14 accc-cancer.org | November–December 2017 | OI Approved Drugs • Bayer HealthCare Pharmaceuticals, Inc. (bayer.com) announced that the U.S. Food and Drug Administration (FDA) has approved Aliqopa™ (copanlisib) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. • The …
JA12-Issues
Amgen-SafetyNetPatientApplicationFormInstructions
JA05-Tools